Cancer clinical trials in the region Grand Est
271 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Lung cancer
#NCT05967689
#2023-503865-48-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Systemic Treatment-Naive
10 recruiting sites
Taiho Oncology
Phase 2
Lymphoma
#NCT06558604
#2023-506706-40-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II)
Disseminated (stage III and IV)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
1
Required previous treatments
Chemotherapy
Targeted therapy
Excluded previous treatments
Bispecific T-cell engager antibodies
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Lymphoma
#NCT06558604
#2023-506706-40-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II)
Disseminated (stage III and IV)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Bispecific T-cell engager antibodies
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Lymphoma
#NCT06558604
#2023-506706-40-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II)
Disseminated (stage III and IV)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Bispecific T-cell engager antibodies
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT04602377
#2024-515310-40-01
Required histologic types
Other ovarian cancer
Required disease stage
Localized
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
6 recruiting sites
ARCAGY/ GINECO GROUP
Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT05872204
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Other ovarian cancer
Required histologic sub types
Serous low grade carcinoma (LGSOC)
Endometrioid carcinoma
Stromal cells and sex cords tumor
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Universitaire Ziekenhuizen KU Leuven
Phase 2
Endometrial cancer
#NCT06906341
#2024-517432-21-00
Required FIGO stages
Stage III
Stage IV
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Corcept Therapeutics
Phase 2
Lung cancer
#NCT06712316
#2024-515764-31-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
Excluded previous treatments at localized stage
Immunotherapy
Chemotherapy
Targeted therapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Bispecific T-cell engager antibodies
11 recruiting sites
BioNTech SE
Phase 2
Lymphoma
#NCT05283720
#2023-505347-38-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Indolent transformed lymphoma
Required number of previous lines of therapy
None
1
2
3 or more
Excluded previous treatments
Bispecific T-cell engager antibodies
8 recruiting sites
Abbvie
Phase 2
Stomach and esophageal cancer
#NCT07205731
Required histologic types
Esophagus
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
CHU de Clermont-Ferrand